{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:38:05Z","timestamp":1790984285225,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,6,8]],"date-time":"2006-06-08T00:00:00Z","timestamp":1149724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To assess the improvements in symptoms, quality of life (QoL), discomfort and satisfaction in patients with symptomatic benign prostatic hyperplasia (BPH) treated with dutasteride in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>In a prospective, multicentre open\u2010label study, we evaluated the efficacy and safety in clinical practice of dutasteride, 0.5\u2003mg\/day for 24\u2003weeks, in patients with symptomatic BPH. The primary endpoint was the proportion of patients achieving at least a 3\u2010point decrease from baseline in the International Prostate Symptom Score (IPSS) after 24\u2003weeks of treatment. The secondary endpoints included changes from baseline in measures of QoL (IPSS item 8 and BPH Impact Index score, BII), and patient discomfort and satisfaction (visual analogue scales, VAS) at 12 and 24 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of the 366 patients assessed, 72.5% achieved at least a 3\u2010point reduction in IPSS at 24 weeks; the IPSS decreased from 15.3 at baseline to 10.2 at 12 weeks, and to 9.1 at 24 weeks. There were significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001) decreases in all the individual IPSS items at 12 and 24 weeks, with more marked improvements in voiding symptoms than storage symptoms. There were also significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001) improvements in the BII and VAS scores for patient discomfort and satisfaction at both times.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Dutasteride treatment for 24\u2003weeks significantly improved BPH symptoms, QoL and patient discomfort and satisfaction, and was well tolerated in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06241.x","type":"journal-article","created":{"date-parts":[[2006,6,8]],"date-time":"2006-06-08T13:33:44Z","timestamp":1149773624000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice"],"prefix":"10.1111","volume":"98","author":[{"given":"FRAN\u00c7OIS","family":"DESGRANDCHAMPS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEPHANE","family":"DROUPY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JACQUES","family":"IRANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTIAN","family":"SAUSSINE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREA","family":"COMENDUCCI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,6,8]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC).Prostate Enlargement. Benign Prostatic Hyperplasia. NIH publications no. 04\u20133012 2004Available at:http:\/\/kidney.niddk.nih.gov\/kudiseases\/pubs\/prostateenlargement\/. Accessed March 2006"},{"key":"e_1_2_7_3_2","first-page":"79","volume-title":"Proceedings of the Fifth International Consultation on Benign Prostatic Hyperplasia.","author":"Lee C","year":"2001"},{"key":"e_1_2_7_4_2","first-page":"340","article-title":"Origin and evolution of benign prostatic enlargement","volume":"15","author":"McNeal J","year":"1978","journal-title":"Invest Urol"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.07.016"},{"key":"e_1_2_7_6_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations","volume":"170","author":"AUA Practice Guidelines Committee.","year":"2003","journal-title":"J Urol"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030330"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.01.001"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01905-2"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05686.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005047"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008801308886"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(94)80165-7"},{"key":"e_1_2_7_14_2","author":"Agence Nationale d\u2019accreditation et d\u2019Evaluation en Sante (ANAES","year":"2003","journal-title":"Guidelines, Department for diagnosis and treatment of benign prostatic hyperplasia"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000049784"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01402-9"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66780-6"},{"issue":"4","key":"e_1_2_7_18_2","first-page":"AS145","article-title":"Measuring disease\u2010specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urologic Association","volume":"33","author":"Barry MJ","year":"1995","journal-title":"Med Care"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780080704"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01300-0"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00066-0"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802263380901"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05240.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000049884"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01155-4"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04310.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.08.015"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000474467"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05347.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06241.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06241.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:34:38Z","timestamp":1761752078000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06241.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06241.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06241.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,8]]},"assertion":[{"value":"2006-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}